RMCM
CRBP icon

Reynders McVeigh Capital Management’s Corbus Pharmaceuticals CRBP Stock Holding History

Reynders McVeigh Capital Management’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-667
Closed -$39K – 234
2021
Q1 		$39K Hold
667
– – ﹤0.01% 228
2020
Q4 		$25K Buy
+667
New +$24.9K ﹤0.01% 222

Other funds holding CRBP

EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $299B AUM 28.69% 1-Year Est. Return
IEFM
IQ EQ Fund Management Dublin 2, Ireland $1.32B AUM 31.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

Reynders McVeigh Capital Management's CRBP Position: Q2 2021 in Review

Reynders McVeigh Capital Management sold out of Corbus Pharmaceuticals (CRBP) in Q2 2021, closing a stake of 667 shares — an estimated $39K sold.

Reynders McVeigh Capital Management first reported a position in CRBP in Q4 2020 and held it in 2 quarters. The position peaked at $39K in Q1 2021. 98 funds tracked by Wall St. Rank hold CRBP as of Q2 2021.

  • Reynders McVeigh Capital Management reported no remaining Corbus Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Reynders McVeigh Capital Management sold 667 Corbus Pharmaceuticals shares in Q2 2021, an estimated $39K.
  • Reynders McVeigh Capital Management first reported a position in Corbus Pharmaceuticals in Q4 2020 and held it in 2 quarters.
  • Reynders McVeigh Capital Management's Corbus Pharmaceuticals position peaked at $39K in Q1 2021.
  • 98 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q2 2021.

Based on Reynders McVeigh Capital Management's 13F filing for Q2 2021, filed 12 Aug 2021.